Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ovarian Neoplasms

  Free Subscription

Articles published in
Int J Cancer
    July 2022
  1. BHATT A, Bhandoria G, Kepenekian V, Bakrin N, et al
    Comments on ' Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial'.
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34220.
    >> Share

  2. KOOLE SN, Schouten PC, van Driel WJ, Sonke GS, et al
    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial".
    Int J Cancer. 2022 Jul 20. doi: 10.1002/ijc.34219.
    >> Share

    June 2022
  3. HUSBY A, Wohlfahrt J, Melbye M
    Pregnancy duration and ovarian cancer risk: a 50-year nationwide cohort study.
    Int J Cancer. 2022 Jun 24. doi: 10.1002/ijc.34192.
    >> Share

  4. BAANDRUP L, Galanakis M, Hannibal CG, Dehlendorff C, et al
    Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis - the Extreme study.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34171.
    >> Share

  5. ATWAL A, Snowsill T, Dandy MC, Krum T, et al
    The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34165.
    >> Share

  6. TODISCO E, Gigli F, Ronchini C, Amato V, et al
    Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes.
    Int J Cancer. 2022 Jun 13. doi: 10.1002/ijc.34162.
    >> Share

  7. SA JK, Kim J, Kang S, Kim SW, et al
    Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing; A Korean Gynecologic Oncology Group study (KGOG 3047).
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34150.
    >> Share

    May 2022
  8. HARRIS HR, Guertin KA, Camacho TF, Johnson CE, et al
    Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium.
    Int J Cancer. 2022 May 28. doi: 10.1002/ijc.34141.
    >> Share

  9. KOOLE SN, Schouten PC, Hauke J, Kluin RJC, et al
    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer - results from the phase III OVHIPEC trial.
    Int J Cancer. 2022 May 18. doi: 10.1002/ijc.34124.
    >> Share

  10. JAIN S, Nadeem N, Ulfenborg B, Makela M, et al
    Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
    Int J Cancer. 2022 May 9. doi: 10.1002/ijc.34111.
    >> Share

    April 2022
  11. ROMANI C, Capoferri D, Reijnen C, Lonardi S, et al
    L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
    Int J Cancer. 2022 Apr 16. doi: 10.1002/ijc.34035.
    >> Share

  12. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
    Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
    Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
    >> Share

    March 2022
  13. CABASAG CJ, Fagan PJ, Ferlay J, Vignat J, et al
    Ovarian cancer today and tomorrow: a global assessment by world region and Human Development Index using GLOBOCAN 2020.
    Int J Cancer. 2022 Mar 23. doi: 10.1002/ijc.34002.
    >> Share

    February 2022
  14. LUPIA M, Melocchi V, Bizzaro F, Lo Riso P, et al
    Integrated molecular profiling of patient-derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities.
    Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33983.
    >> Share

    October 2021
  15. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    >> Share

  16. SKOLD C, Koliadi A, Enblad G, Stalberg K, et al
    Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes.
    Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33844.
    >> Share

    September 2021
  17. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    >> Share

  18. IYOSHI S, Yoshihara M, Nakamura K, Sugiyama M, et al
    Pro-tumoral behavior of omental adipocyte-derived fibroblasts in tumor microenvironment at the metastatic site of ovarian cancer.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33770.
    >> Share

    August 2021
  19. WANG T, Jake-Schoffman DE, Townsend MK, Vinci C, et al
    Early life physical activity and risk of ovarian cancer in adulthood.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33760.
    >> Share

    July 2021
  20. COUGHLAN AY, Testa G
    Exploiting epigenetic dependencies in ovarian cancer therapy.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33727.
    >> Share

    June 2021
  21. DARELIUS A, Kristjansdottir B, Dahm-Kahler P, Strandell A, et al
    Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714.
    >> Share

  22. PAVONE R, Pacquement H, Pasquet M, Sudour-Bonnange H, et al
    Childhood ovarian non-seminomatous germ cell tumors: A Highly Curable Disease With Few Long-Term Treatment-Related Toxicities. Results of the French TGM95 study.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33710.
    >> Share

    May 2021
  23. WANG T, Townsend MK, Eliassen AH, Terry KL, et al
    Pre- and post-diagnosis leisure time physical activity and survival following diagnosis with ovarian cancer.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33676.
    >> Share

    April 2021
  24. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    >> Share

  25. CHRISTAKOUDI S, Pagoni P, Ferrari P, Cross AJ, et al
    Weight change in middle adulthood and risk of cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
    Int J Cancer. 2021;148:1637-1651.
    >> Share

    March 2021
  26. CROSBIE EJ, Flaum N, Harkness EF, Clayton RD, et al
    Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    Int J Cancer. 2021;148:1155-1163.
    >> Share

    February 2021
  27. YANG J, Sasamoto N, Babic A, Vitonis AF, et al
    Intrauterine device use and risk of ovarian cancer: results from the New England Case-Control study and Nurses' Health Studies.
    Int J Cancer. 2021 Feb 26. doi: 10.1002/ijc.33531.
    >> Share

    January 2021
  28. BETHEA TN, Ochs-Balcom HM, Bandera EV, Beeghly-Fadiel A, et al
    First- and second-degree family history of ovarian and breast cancer in relation to risk of invasive ovarian cancer in African American and White women.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33493.
    >> Share

  29. PREOBRAZHENSKAYA EV, Shleykina AU, Gorustovich OA, Martianov AS, et al
    Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Int J Cancer. 2021;148:203-210.
    >> Share

    November 2020
  30. AN Y, Yang Q
    Tumor-associated macrophage targeted therapeutics in ovarian cancer.
    Int J Cancer. 2020 Nov 24. doi: 10.1002/ijc.33408.
    >> Share

  31. KESSOUS R, Wissing MD, Laskov I, Abitbol J, et al
    Multiple lines of chemotherapy for patients with high-grade ovarian cancer - predictors for response and effect on survival.
    Int J Cancer. 2020 Nov 16. doi: 10.1002/ijc.33395.
    >> Share

    October 2020
  32. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    >> Share

    September 2020
  33. ONG JS, Derks EM, Eriksson M, An J, et al
    Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.
    Int J Cancer. 2020 Sep 25. doi: 10.1002/ijc.33308.
    >> Share

  34. STALIN J, Traboulsi W, Vivancos-Stalin L, Nollet M, et al
    Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
    Int J Cancer. 2020;147:1666-1679.
    >> Share

  35. APOSTOLOU P, Fostira F, Kouroussis C, Kalfakakou D, et al
    BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Int J Cancer. 2020;147:1334-1342.
    >> Share

    August 2020
  36. TODISCO E, Gigli F, Mantiero M, Sammassimo S, et al
    Clinical presentation, diagnosis and management of Therapy-Related Hematological Disorders in Women with Epithelial Ovarian Cancer treated with Chemotherapy and Poly-ADP-Ribose Polymerase Inhibitors (PARP-i): a single Center experience.
    Int J Cancer. 2020 Aug 28. doi: 10.1002/ijc.33269.
    >> Share

    July 2020
  37. PANOUTSOPOULOU K, Avgeris M, Magkou P, Mavridis K, et al
    miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33182.
    >> Share

    June 2020
  38. HANSEN JM, Nagle CM, Ibiebele TI, Grant PT, et al
    A healthy lifestyle and survival among women with ovarian cancer.
    Int J Cancer. 2020 Jun 16. doi: 10.1002/ijc.33155.
    >> Share

    April 2020
  39. JIANG YT, Gong TT, Zhang JY, Li XQ, et al
    Infertility and ovarian cancer risk: evidence from nine prospective cohort studies.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33012.
    >> Share

  40. JUNG M, Gao J, Cheung L, Bongers A, et al
    ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
    Int J Cancer. 2020 Apr 10. doi: 10.1002/ijc.33005.
    >> Share

  41. IDAHL A, Cornet CL, Maldonado SG, Waterboer T, et al
    Serologic markers of Chlamydia trachomatis and other sexually transmitted infections and subsequent ovarian cancer risk: Results from the EPIC cohort.
    Int J Cancer. 2020 Apr 3. doi: 10.1002/ijc.32999.
    >> Share

    March 2020
  42. GONG Y, Yang J, Wang Y, Xue L, et al
    Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites.
    Int J Cancer. 2020 Mar 24. doi: 10.1002/ijc.32990.
    >> Share

  43. SINGH A, Gupta S, Badarukhiya JA, Sachan M, et al
    "Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer".
    Int J Cancer. 2020 Mar 19. doi: 10.1002/ijc.32984.
    >> Share

  44. ESSERS PBM, van der Heijden M, Vossen D, de Roest RH, et al
    Ovarian cancer derived copy number alterations signatures are prognostic in chemoradiotherapy treated head and neck squamous cell carcinoma.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32962.
    >> Share

    February 2020
  45. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    >> Share

  46. BENVENUTO G, Todeschini P, Paracchini L, Calura E, et al
    Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    Int J Cancer. 2020 Feb 25. doi: 10.1002/ijc.32935.
    >> Share

  47. KOTSOPOULOS J, Narod SA
    Prophylactic salpingectomy for the prevention of ovarian cancer; who should we target?
    Int J Cancer. 2020 Feb 9. doi: 10.1002/ijc.32916.
    >> Share

  48. REIJNEN C, Kusters-Vandevelde HVN, Ligtenberg MJL, Bulten J, et al
    Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome.
    Int J Cancer. 2020 Feb 5. doi: 10.1002/ijc.32907.
    >> Share

    January 2020
  49. HANNIBAL CG, Frederiksen K, Vang R, Kurman RJ, et al
    Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: a nationwide-based study.
    Int J Cancer. 2020 Jan 12. doi: 10.1002/ijc.32864.
    >> Share

  50. YOSHIHARA M, Kajiyama H, Yokoi A, Sugiyama M, et al
    Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.
    Int J Cancer. 2020 Jan 6. doi: 10.1002/ijc.32854.
    >> Share

    December 2019
  51. RAMRAJ SK, Elayapillai SP, Pelikan RC, Zhao YD, et al
    Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53.
    Int J Cancer. 2019 Dec 17. doi: 10.1002/ijc.32830.
    >> Share

  52. WOLF D, Fiegl H, Zeimet AG, Wieser V, et al
    High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.
    Int J Cancer. 2019 Dec 4. doi: 10.1002/ijc.32818.
    >> Share

    November 2019
  53. WANG T, Townsend MK, Simmons V, Terry KL, et al
    Pre- and Post- Diagnosis Smoking and Survival Following Diagnosis with Ovarian Cancer.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32773.
    >> Share

  54. SOKOLENKO AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, et al
    Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776.
    >> Share

    October 2019
  55. KRATZER TB, Weinstein SJ, Albanes D, Mondul AM, et al
    Vitamin D Binding Protein and Risk of Renal Cell Carcinoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Int J Cancer. 2019 Oct 29. doi: 10.1002/ijc.32758.
    >> Share

  56. FELIX AS, McLaughlin EM, Caan BJ, Cohn DE, et al
    Guideline-concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32740.
    >> Share

  57. LEE YJ, Kim D, Shim JE, Bae SJ, et al
    Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2019 Oct 11. doi: 10.1002/ijc.32729.
    >> Share

  58. SIMIN J, Rulla MT, Callens S, Engstrand L, et al
    Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
    Int J Cancer. 2019 Oct 4. doi: 10.1002/ijc.32706.
    >> Share

  59. QIU JJ, Lin XJ, Tang XY, Zheng TT, et al
    Long Noncoding RNA TC0101441 induces epithelial-mesenchymal transition in epithelial ovarian cancer metastasis by downregulating KiSS1.
    Int J Cancer. 2019 Oct 2. doi: 10.1002/ijc.32692.
    >> Share

    September 2019
  60. YI T, Feng Y, Sundaram R, Tie Y, et al
    Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    Int J Cancer. 2019;145:1209-1220.
    >> Share

    July 2019
  61. RAAB M, Kobayashi NF, Becker S, Kurunci-Csacsko E, et al
    Boosting the apoptotic response of high grade serous ovarian cancers with CCNE1-amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32559.
    >> Share

    March 2019
  62. BALLABIO S, Craparotta I, Paracchini L, Mannarino L, et al
    Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number variation in 3p26.2 and 8q24.3.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32288.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016